Cite
Bewersdorf JP, Derkach A, Gowda L, et al. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021;62(14):3394-3401doi: 10.1080/10428194.2021.1966788.
Bewersdorf, J. P., Derkach, A., Gowda, L., Menghrajani, K., DeWolf, S., Ruiz, J. D., Ponce, D. M., Shaffer, B. C., Tamari, R., Young, J. W., Jakubowski, A. A., Gyurkocza, B., Chan, A., Xiao, W., Glass, J., King, A. C., Cai, S. F., Daniyan, A., Famulare, C., Cuello, B. M., Podoltsev, N. A., Roshal, M., Giralt, S., Perales, M. A., Seropian, S., Cho, C., Zeidan, A. M., Prebet, T., Stein, E. M., Tallman, M. S., Goldberg, A. D., & Stahl, M. (2021). Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & lymphoma, 62(14), 3394-3401. https://doi.org/10.1080/10428194.2021.1966788
Bewersdorf, Jan Philipp, et al. "Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant." Leukemia & lymphoma vol. 62,14 (2021): 3394-3401. doi: https://doi.org/10.1080/10428194.2021.1966788
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021 Dec;62(14):3394-3401. doi: 10.1080/10428194.2021.1966788. Epub 2021 Sep 03. PMID: 34477024.
Copy
Download .nbib